Vixotrigine

Vixotrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), formerly known as raxatrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).^[1]^[2]^[3] Vixotrigine was originally claimed to be a selective central Na_v1.3 blocker, but was subsequently redefined as a selective peripheral Na_v1.7 blocker.^{[citation needed]} Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker.^{[citation needed]} As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.^[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.^[4]

Clinical data

Other names	Raxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of administration	By mouth
ATC code	None
Identifiers
IUPAC name (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
CAS Number	934240-30-9 934240-35-4 (mesylate)
PubChem CID	16046068
ChemSpider	13174481
UNII	QQS4J85K6Y
KEGG	D11179
CompTox Dashboard (EPA)	DTXSID901031867
Chemical and physical data
Formula	C₁₈H₁₉FN₂O₂
Molar mass	314.360 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
InChI InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1 Key:JESCETIFNOFKEU-SJORKVTESA-N

See also